Buy now as a tactical, support-based entry: price (22.41 pre-market) is sitting just above key support S1=22.234, offering favorable risk/reward for an impatient trader.
Upside targets for a quick move: Pivot=24.06 first, then R1=25.886 if momentum improves.
The trend is not fully bullish (MACD still negative), so this is a bounce/swing setup rather than a “trend-chasing” buy.
Trend/pressure: MACD histogram -0.255 (below zero) and negatively contracting → bearish momentum is easing but not reversed.
RSI(6)=39.399 → leaning weak/near-oversold; often consistent with a short-term bounce attempt rather than a breakdown if support holds.
Moving averages: converging → consolidation phase; market is deciding direction.
Key levels: Support S1=22.234 (critical), S2=21.106 (next downside). Resistance Pivot=24.06 (first reclaim level), then R1=25.886 and R2=27.014.
Pattern-based odds: similar-pattern stats imply moderate upside bias over time (next day +1.42%, next week +2.02%, next month +4.86%) but only ~40% probability—so the edge comes mainly from the tight support entry.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning (OI): Put/Call OI ratio 0.06 (calls dominate; 181 call OI vs 11 put OI) → bullish skew in outstanding positions.
Activity: today’s option volume is 0 → sentiment read is based on positioning, not fresh flow.
Volatility: 30D IV 86.4 vs historical vol 37.92 → options are pricing large moves; IV percentile 39.2 / IV rank 21.88 suggests IV is not at extremes vs its own history.
Technical Summary
Sell
9
Buy
2
Positive Catalysts
Analyst support: Northland reiterated Outperform and raised PT to $34 (from $31), also naming BLFS a 2026 Top Pick.
Business narrative: “pure play” biopreservation layer in cell & gene therapy—sticky integration across development to commercialization (per analyst thesis).
Technical setup: price is very near S1 support, which can trigger short-term dip-buying/bounce behavior.
Neutral/Negative Catalysts
Profitability deterioration YoY despite revenue growth (net income and EPS down sharply).
Net income: $0.621M, -136.47% YoY (material deterioration vs prior-year profitability).
EPS: $0.01, -125.00% YoY.
Gross margin: 61.36%, down 1.37% YoY (slight margin compression).
Read-through: growth is strong, but earnings quality/trend is currently the weak spot.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: Northland raised price target to $34 from $31 (2026-01-05) and maintained Outperform; BLFS also tagged as a 2026 Top Pick.
Wall Street pro view (pros): structural “locked-in” role in biopreservation for cell & gene therapy programs; perceived durable demand and platform positioning.
Wall Street con view (cons): current financials show profitability/EPS weakness and slight margin compression, which can cap near-term multiple expansion.
Holdings/trading behavior: Hedge funds neutral (no notable last-quarter trend); insiders neutral (no notable last-month trend).
Influential/politician activity: No recent congress trading data available in the last 90 days.
Wall Street analysts forecast BLFS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLFS is 33.2 USD with a low forecast of 32 USD and a high forecast of 34 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast BLFS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLFS is 33.2 USD with a low forecast of 32 USD and a high forecast of 34 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 22.020
Low
32
Averages
33.2
High
34
Current: 22.020
Low
32
Averages
33.2
High
34
Northland
Outperform
maintain
$31 -> $34
AI Analysis
2026-01-05
Reason
Northland
Price Target
$31 -> $34
AI Analysis
2026-01-05
maintain
Outperform
Reason
Northland raised the firm's price target on BioLife Solutions to $34 from $31 and keeps an Outperform rating on the shares, which were also named a 2026 Top Pick. Following its re-establishment as a pure play and its control of the biopreservation layer in cell and gene therapy development, BioLife is "structurally locked into large pharma and biotech programs from initiation through commercialization," the analyst tells investors.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$30 -> $32
2025-08-08
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$30 -> $32
2025-08-08
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on BioLife Solutions to $32 from $30 and keeps a Buy rating on the shares following the Q2 beat.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BLFS
